A5036936997- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Liver Disease Diagnosis and Treatment
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Surgical Treatments
- Cancer Mechanisms and Therapy
- Colorectal and Anal Carcinomas
- Inflammatory Biomarkers in Disease Prognosis
- PI3K/AKT/mTOR signaling in cancer
- Angiogenesis and VEGF in Cancer
- Circular RNAs in diseases
- Cancer-related molecular mechanisms research
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Hepatitis C virus research
- Cancer Treatment and Pharmacology
- Metabolism, Diabetes, and Cancer
- Renal cell carcinoma treatment
- Pancreatitis Pathology and Treatment
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2025
Pfizer (United Kingdom)
2023
Roche (Switzerland)
2023
Novartis (Switzerland)
2023
Jazz Pharmaceuticals (United States)
2023
Abstract Purpose: The aberrant expression of miR-221 is a hallmark human cancers, including hepatocellular carcinoma (HCC), and its involvement in drug resistance, together with proved vivo efficacy anti-miR-221 molecules, strengthen role as an attractive target candidate the oncologic field. discovery biomarkers predicting response to treatments represents clinical challenge personalized treatment era. This study aimed investigate possible circulating biomarker HCC patients undergoing...
We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte (PLR) with the aim to explored their prognostic value in patients advanced hepatocellular carcinoma (HCC) treated sorafenib. 56 HCC receiving sorafenib were available for our analysis. Lymphocyte, neutrophil platelet measured before beginning of treatment after one month. Patient SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) OS (5.6 13.9 = 0.027) respect...
Several studies have reported an association between type 2 diabetes mellitus and hepatocellular carcinoma (HCC). Data from several retrospective meta-analyses highlighted a reduction of about 50% in the risk developing HCC cirrhotic patients treated with metformin for diabetes. The aim this study was to evaluate different outcomes who received or did not receive during treatment sorafenib.We analyzed 93 consecutively sorafenib. Forty-two (45.2%) were diabetic, whom 31 on metformin....
Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved several processes including angiogenic pathway. They very stable biological fluids, turns them into circulating biomarkers. In this study, we considered case series patients with metastatic (m) CRC treated bevacizumab (B)-based treatment, enrolled prospective multicentric Italian Trial Advanced...
The application of non-targeted serum metabolomics profiling represents a noninvasive tool to identify new clinical biomarkers and provide early diagnostic differentiation, insight into the pathological mechanisms underlying hepatocellular carcinoma (HCC) progression. In this study, we used proton Nuclear Magnetic Resonance (1H-NMR) Spectroscopy multivariate data analysis profile metabolome 64 HCC patients, in (n = 28) advanced 36) disease stages. We found that 1H-NMR could discriminate from...
Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related death worldwide, with a low 5-year survival rate even in fully resected early-stage disease. Novel biomarkers to identify patients at higher risk relapse are needed. We studied prognostic value 84 circulating microRNAs (miRNAs) 182 NSCLC (99 adenocarcinoma (ADC), 83 squamous carcinoma (SCC)) from whom peripheral blood samples were collected pre-surgery. miRNA expression was analyzed relation disease-free (DFS) and...
Background and aims The present study to investigate the role of prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated sorafenib. Methods This multicentric included a training cohort 194 HCC three external validation cohorts 129, 76 265 Sorafenib, respectively. PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 total lymphocyte count (per mm3). Univariate multivariate analyses were performed association between...
This study investigated the efficacy of chemoradiotherapy (CRT) followed by durvalumab as neoadjuvant therapy locally advanced rectal cancer.The PANDORA trial is a prospective, phase II, open-label, single-arm, multicenter aimed at evaluating and safety preoperative treatment with (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 administered 825 mg/m2 twice daily). The primary...
Colorectal cancer (CRC) is the third most common in world. A significant survival rate achieved if it detected at an early stage. whole blood screening test, without any attempt to isolate fractions, could be important tool improve detection of colorectal cancer. We searched for candidate markers with a novel approach based on Transcriptome Mapper (TRAM), aimed identifying specific RNAs highest differential expression ratio between tissue and normal samples. This permits large-scale...
Sorafenib is a multi-targeted kinase inhibitor with demonstrated activity in renal cell carcinoma (RCC) and hepatocellular (HCC), it currently used for the treatment of these pathologies. Ongoing clinical trials are studying its other malignancies, such as non-small-cell lung cancer (NSCLC). However, no biological marker known to define either sensitivity or resistance drug. Here we report case patient two synchronous tumors, HCC NSCLC, metastases contralateral bone. The was treated...
There is evidence of a different response to treatment with regard the primary tumor localization (right-sided or left-sided) in patients metastatic colorectal cancer (mCRC). We analyzed outcomes and biomolecular characteristics relation 122 370 enrolled onto phase III prospective multicenter “Italian Trial Advanced Colorectal Cancer (ITACa)”, randomized receive first-line chemotherapy (CT) CT plus bevacizumab (CT + B). RAS BRAF mutations; baseline expression levels circulating vascular...
Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatment of metastatic colorectal cancer (mCRC). However, molecular predictors bevacizumab efficacy have not yet been identified. We analyzed vascular endothelial growth factor (VEGF) and nitric oxide synthase (eNOS) polymorphisms in relation to response bevacizumab. Two hundred thirty-seven patients with mCRC enrolled onto the phase III prospective multicentre randomized "Italian Trial Advanced Colorectal...
So far, no randomized trial or meta-analysis has been conducted on overall survival (OS) and recurrence-free (RFS) factors in patients treated with radiofrequency ablation (RFA) alone. The purpose of this was to evaluate prognostic OS RFS RFA.A primary analysis planned the clinical factor OS. secondary aim. Thirty-four studies published from 2003 2017 were analyzed. They included 11,216 hepatocellular carcinoma patients.The results showed that Child-Pugh B vs A (HR =2.32; 95% CI: 2.201-2.69;...
Abstract Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety efficacy metronomic as second-line treatment. This multicentric analyzed data patients unresponsive or intolerant sorafenib treatment with best supportive care (BSC).Median progression free survival 3.1 months treated (95%CI: 2.7–3.5). Median overall 12.0 (95% CI: 10.7–15.8) receiving capecitabine, while 9.0 6.5–13.9) BSC. result...
// Andrea Casadei Gardini 1, * , Giorgia Marisi 2, Luca Faloppi 3 Emanuela Scarpi 4 Francesco Giuseppe Foschi 5 Massimo Iavarone 6 Gianfranco Lauletta 7 Jody Corbelli 8 Martina Valgiusti 1 Floriana Facchetti Cristina della Corte Maria Neri 9 Stefano Tamberi Cascinu Mario Scartozzi 10 Dino Amadori Oriana Nanni Elena Tenti Paola Ulivi ** Giovanni Frassineti Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy 2...
Sorafenib has been established as the standard of care for patients with advanced hepatocellular carcinoma (HCC) since 2007 on basis two landmark trials (SHARP and Asia-Pacific). Ten years have passed then and, despite much research in field, still no validated real-life prognostic markers are available HCC treated this drug. Therefore, going through 10 into sorafenib several Italian Cancer Centers, we conducted a field-practice study aimed at identifying baseline clinical factors that could...
Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC).To explore the value IIs mCRC patients treated with first-line chemotherapy plus Bev.One hundred eighty-two diagnosed first line Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate...
Abstract Lynch‐like syndrome (LLS) presents very similar clinicopathological characteristics to Lynch (LS) but the mechanism for cancer predisposition remains unknown. The present study aims investigate causal of LLS by a comprehensive genetic and epigenetic approach. Thirty‐two 34 LS patients with colorectal (CRC) fitting Amsterdam Bethesda criteria were included, along 29 CRC sporadic patients, analyzed presence pathogenic variants in 94 genes associated hereditary tumors. cohorts also...